UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
Group therapy holds promise for psychedelic-based treatments
“Those meetings are beautiful,” he says. “They’ve given me a real appreciation of how empowering it is for a cancer patient to help other cancer patients.”
Is the requirement for first-person experience of psychedelic drugs a justified component of a psychedelic therapist’s training?
Requiring trainees to take psychedelic drugs does not seem ethically legitimate.
The impact of psychedelic drugs on anxiety and depression in advanced cancer or other life-threatening disease: A systematic review with meta-analysis
Although the results are promising, future trials are needed to assess the optimal psychedelic, dose, number of sessions required.
Psychedelics and psychological strengths
Classical psychedelic users showed greater psychological strengths and well-being, and lower levels of distress.
Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors
We hope for this article to support clinical research on PAGP by presenting a therapeutic framework and outlining its mechanisms and challenges.
Association between mystical-type experiences under psychedelics and improvements in well-being or mental health – A comprehensive review of the evidence
The identified studies suggest that mystical-type experiences under psychedelics are associated with improvements in some areas of well-being.
Psychedelic medicine and the clinical application of hallucinogens
Although humans have used hallucinogens ritualistically for thousands of years, interest in their clinical use for the treatment of mental illness began in the 1950s.
Ayahuasca – a review of historical, pharmacological, and therapeutic aspects
Ayahuasca is a promising psychedelic agent that warrants greater empirical attention regarding its basic neurochemical mechanisms of action and its therapeutic uses.
A retrospective study to determine the impact of psychedelic therapy for dimensional measures of wellness: A qualitative analysis of response data
The use of various psychedelic medicines appears to be associated with a broad range of qualitative experiences that could help clarify ... how they impact wellness in the future.
Could MDMA’s UK approval be fast tracked by forthcoming Reciprocal Drug Approval Procedure with FDA?
Might MAPS PBC’s MDMA-assisted therapy for PTSD be among the first products considered under this new UK reciprocal drug approval pathway?
Beckley Psytech receives FDA approval for Phase IIb study of BPL-003, a novel synthetic formulation of 5-MeO-DMT
This Phase IIb randomised, dose-finding study will evaluate the effects of a single dose of BPL-003 in patients with moderate to severe TRD who are not taking concomitant antidepressants.
The Psychedelic Educators Network
Christine Ziemer has established an international network of professors and instructors who are teaching (or, plan to teach) psychedelics-related courses.
Experiences of psilocybin treatment for clinical conditions: A qualitative meta-synthesis
The synthesis of findings identified three themes that were common across the studies despite the health condition: acceptance, connection and transformation.
The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists
we suggest there is scope to develop up-to-date education about psychedelics for psychiatrists.
Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample
Lifetime MDMA/ecstasy use was associated with lowered odds of three of our four social impairment outcomes.